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Analysis of renal tubular electrolyte transporter genes in seven
patients with hypokalemic metabolic alkalosis.
Background. Disorders that manifest hypokalemic metabolic
alkalosis, such as Bartter’s syndrome and Gitelman’s syndrome,
are caused by the malfunction of renal tubular electrolyte trans-
porters. Bartter’s syndrome may be linked to dysfunction of
Na-K-2Cl cotransporter (NKCC2), renal outer medullary K
channel (ROMK), or Cl channel Kb (ClC-Kb), while Gitel-
man’s syndrome may be linked to Na-Cl cotransporter (NCCT)
dysfunction. However, previous genetic analyses in these syn-
dromes have included many heterozygotes for each gene and
there has been no further analysis of other genes. Thus, to
clarify the interaction of these transporter genes, in the present
study we investigated all 4 transporter genes in 7 patients with
hypokalemic metabolic alkalosis.
Methods. Seven patients from 5 families (patients A–G)
were collected, and a mutation analysis of the 4 renal electrolyte
transporter genes was performed by direct sequencing.
Results. We identified 12 mutations in these 7 patients. Three
mutations (del245Y in NKCC2, R1009X in NCCT, V524I
in ClC-Kb) have not been reported previously. In NKCC2
gene screening, patient A was homozygous for del245Y. In
ClC-Kb gene screening, L27R was detected in patients B, D,
and E. V524I was detected in patient C. Both T562M and
E578K were observed in patients B and E. In NCCT gene
screening, patients B–G shared a common novel mutation,
R1009X, and patients D, E, F, and G carried this mutation in
both alleles. Patients B and C carried R1009X in one allele,
and a 6-amino acid insertion in exon 6 and L849H in another
allele, respectively. The 4 other mutations did not result in
any amino acid exchange. Despite the NCCT gene mutation,
patients C and E showed normomagnesemia.
Conclusion. Our findings demonstrate that in Bartter’s and
Gitelman’s syndromes, it may not be uncommon to see muta-
tions in several causative transporter genes.
Bartter’s syndrome and Gitelman’s syndrome are
characterized by hypokalemic metabolic alkalosis in
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combination with elevated plasma concentrations of re-
nin and aldosterone [1, 2]. In contrast to Bartter’s syn-
drome, Gitelman’s syndrome is usually found in older
children and young adults. Patients with Bartter’s syn-
drome have normal or decreased serum magnesium lev-
els, normal urinary magnesium excretion, and normal or
increased urinary calcium excretion. Patients with Gitel-
man’s syndrome have hypomagnesemia, increased uri-
nary magnesium, and decreased urinary calcium excre-
tion [3]. However, in some cases, it is very difficult to
differentiate these two disorders based on clinical and
chemical laboratory findings [4].
Recent studies on renal tubular electrolyte transporter
genes have demonstrated loss-of-function mutations in
the genes encoding sodium-potassium-chloride cotrans-
porter (NKCC2), renal outer medullary potassium chan-
nel (ROMK), chloride channel (ClC-Kb), and sodium-
chloride cotransporter (NCCT), respectively [5–8]. The
first three gene mutations were associated with Bartter’s
syndrome and the last was associated with Gitelman’s
syndrome. Thus, Bartter’s syndrome is caused by a mal-
function of NKCC2, ROMK, and ClC-Kb, while Gitel-
man’s syndrome is caused by a malfunction of NCCT.
Peters et al [9] reported that 65 (61 homozygotes and 4
heterozygotes) of 85 patients with Bartter’s-like syn-
dromes (including Gitelman’s syndrome) had molecular
defects in NKCC2, ROMK, ClC-Kb, or NCCT. How-
ever, previous analyses of these genes have usually in-
cluded many heterozygotes for each gene and did not
further examine other genes. To clarify the relationship
between phenotype and genotype, in the present study
we investigated possible mutations in the 4 genes encod-
ing NKCC2, ROMK, ClC-Kb, and NCCT in 7 patients
with hypokalemic metabolic alkalosis (2 patients were
clinically diagnosed as Gitelman’s syndrome, and the
other 5 patients were diagnosed as Bartter’s syndrome)
in Okinawa, Japan. We identified 2 NKCC2 gene muta-
tions, 5 ClC-Kb gene mutations, and 5 NCCT gene muta-
tions in these 7 patients.
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Table 1. Clinical characteristics of the seven patients
Presentation Date GA BW Height Weight
Patient years Sex of birth weeks g cm kg Symptoms
A 0 F Nov. 1996 30 1225 80 (4.4 SD)a 9 (3.1 SD)a Growth retardation, polyuria
B 8 F Mar. 1991 40 3705 138 (0.0 SD)a 26 (1.1 SD)a Fatigue, cramp, muscle weakness
C 8 F Dec. 1984 39 2950 164 (1.4 SD) 64 Fatigue, cramp, muscle weakness
D 10 M Oct. 1973 38 2450 160 (1.8 SD) 65 Fatigue, cramp, muscle weakness
E 12 F Oct. 1974 41 2950 146 (2.2 SD) 37 Fatigue, cramp, muscle weakness
F 20 M Jul. 1970 40 3415 170 (0.0 SD) 67 Fatigue, cramp, muscle weakness
G 20 F Nov. 1974 39 3655 157 (0.05 SD) 52 Fatigue, cramp, muscle weakness
Abbreviations are: M, male; F, female, GA, gestational age; BW, birth weight. Standard deviation (SD) at corresponding age in Japanese are shown.
a Height and weight of patients A and B at first referral to our hospital, 3 years and 8 months, and 10 years and 3 months, respectively
Table 2. Biochemical findings in the seven patients
Na K Cl Mg HCO3 PRA Aldo Ca/Cr
Patient mmol/L mmol/L mmol/L mmol/L pH mmol/L BE ng/mL/hr pg/ml mol/mol
A 135 2.3 87 0.95 7.51 27.6 5.1 over 20 110 4.10
B 132 2.4 87 0.58 7.45 33.0 8.0 12 95 0.06
C 138 2.9 100 0.91 7.51 27.6 5.1 3.2 50 0.00
D 137 2.1 92 0.54 7.47 27.3 4.5 20 110 0.02
E 139 2.6 100 0.74 7.49 27.8 5.6 over 20 650 0.03
F 136 1.7 95 0.54 7.46 29.3 5.7 over 20 120 0.02
G 134 2.2 103 0.65 7.46 31.8 7.8 7.8 51 0.01
Normal range 135–145 3.6–4.5 98–109 0.7–1.1 7.35–7.45 23–27 4–2 0.3–5.4 35–240 0.2–0.6
Abbreivations are: BE, base excess; PRA, plasma renin activity; Aldo, aldosterone; Ca/Cr, ratio of calcium to creatinine in the urine.
METHODS
Patients
Seven patients from 5 families with hypokalemic meta-
bolic alkalosis were collected from Ryukyu University
Hospital, Yonabaru Chuo Hospital, and Nanbu Tokusyu-
kai Hospital in Okinawa, Japan. Patient A was referred
to our hospital for clinical evaluation of short stature,
hypokalemia, and polyuria. As shown in Table 1, patients
B–G had intermittent cramps, fatigue, and muscle weak-
ness. Patients B–G initially presented at older than 8
years of age. Patients D and E tended to have a slightly
short stature. Patients D and E and patients F and G are
siblings, respectively. Representative biochemical data are
shown in Table 2. All patients had severe hypokalemia
(less than 3 mmol/L) and metabolic alkalosis. Venous
blood was drawn after an overnight fast. Informed con-
sent was obtained from the patients or their parents.
Mutation analysis
Sets of primer pairs for renal tubular electrolyte trans-
porter genes NKCC2 gene. Specific primer pairs that am-
plified the splice sites and the 26 exons of this gene were
generated based on data reported by Simon et al [5]
(Table 3). Primer pairs were also chosen to amplify the
2 additional isoforms of exon 4 (Table 3) [10].
ROMK gene. Previous studies have demonstrated
that the gene encoding human ROMK produces 5 dis-
tinct transcripts (ROMK 1–5) by differential splicing of
its 5 exons [11, 12]. All 5 transcripts share an exon 5 that
encodes most of the ROMK protein. Based on the se-
quence of ROMK, sets of primer pairs were generated
to amplify the coding sequences for exons 1–5 (Table 4).
ClC-Kb gene. Primers that amplify the 19 exons of
ClC-Kb gene together with their splice sites were gener-
ated based on a previous report [7] (Table 5).
NCCT gene. Twenty-six pairs of specific primers were
generated to amplify all 26 exons of this gene based on
the data reported by Simon et al [8] and Mastroianni et
al [13] (Table 6).
Polymerase chain reaction (PCR) and direct sequenc-
ing. Genomic DNA was isolated from blood cells using
a Puregen DNA isolation kit (Gentra, Minneapolis, MN,
USA). The exonic regions of each of the 4 transporters,
including intron/exon boundaries, were amplified using
specific primers (Tables 3–6) by polymerase chain reac-
tion (PCR). PCR was carried out using the following
conditions: initial denaturation at 95C for 10 minutes
was followed by 35 cycles of denaturation at 95C for 30
seconds; annealing at 51 to 72C for 30 seconds and
extension at 72C for 1 min in 25 L of reaction mixture
containing 50 to 100 ng of genomic DNA, 1  PCR
buffer (Perkin Elmer Applied Biosystems, Foster City,
CA, USA), 0.2 mmol/L dNTPs, 0.5 mmol/L of each
primer, and 0.5 U AmpliTaq DNA polymerase (PE Ap-
plied Biosystems) with a GeneAmp 9700 system (PE
Applied Biosystems). The reaction was completed with
a final elongation step at 72C for 10 minutes. Lastly,
PCR products were purified with a QIAquick Gel Ex-
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Table 3. PCR primers for mutation analysis in NKCC2
Size T
Primers Exon Sequence (5→3) bp C
NKCC2.1F 1 AACAACCACAAAGTAGATAGCTCAG 547 55
NKCC2.1R CATTCATAGTGTAATGAAAGAGAAG
NKCC2.2F 2–3 ATGGAACCCTTTGTTCATTGACCAA 517 60
NKCC2.3R GTGACCTTCATCTCACATTCAG
NKCC2.4BF 4B TTGATGTTTACCCTAGACTTGCTGG 256 58
NKCC2.4BR GGTGAACTGTTAGAGCCTGTGTTGC
NKCC2.4AF 4A TGCAGCAATAGGGAATCCAAGGAAG 218 58
NKCC2.4AR ATTGTTCGCCTACCCGTAGCAAGT G
NKCC2.4FF 4F CTGAAGTACTGGTGACTTCTCTCAG 213 58
NKCC2.4FR CTCCAGACATTACTAGTA ACCAAGC
NKCC2.5F 5 CTAGCAGTTCCTCAATGTGAAG 256 53
NKCC2.5R ACTAAATTATGCTGCTTGGCAG
NKCC2.6F 6 ATGCTGCAATAAGACTCACATG 229 55
NKCC2.6R CAGGACCTGACCAGCCACTG
NKCC2.7F 7 GATAGAGTCTTTCTGCAGTGGACAC 269 53
NKCC2.7R GTGATGAGGAGGGCAATGGAGAAGT
NKCC2.8F 8 TGGTAACTTAATCTCCTGTACTGTG 272 55
NKCC2.8R TAACCTCTCTAGCTCCTTGTGCTAC
NKCC2.9F 9 GTGATCTATGGTTCTTATTCTGCTC 251 55
NKCC2.9R TGCATTGAAAGCTCACTAGACGTGA
NKCC2.10F 10 TCAGTAGAAAACCGTAAGGGACCAG 303 55
NKCC2.10R CAGTTGCAGATTCAGAAATCTTACT
NKCC2.11F 11–12 TGTAGTTGAAAGCCGTTTGCTTATG 695 55
NKCC2.12R GGAAAGCCCTATGAATAATCAGAAG
NKCC2.13F 13 TTCGAGGCTATAACAGCTGTTCAGC 271 55
NKCC2.13R AACACAGATTGAACACTTTTCACTG
NKCC2.14F 14 GTGCCATGATCATAGTAGAGTG 242 55
NKCC2.14R TGGAAACGCTATTCCAGACAG
NKCC2.15F 15 ATTCATGGTGCACAGAGGAAAGGTC 231 55
NKCC2.15R CTTGTCTCTTATAAAGGAGAGCCAC
NKCC2.16F 16 TCTAAGGTTACAGGCTTCTTGCAGG 240 57
NKCC2.16R TCTCCTCACCCAAAATAATCCAAGA
NKCC2.17F 17 ACAGCAATGTGATATATAATAGCAG 259 59
NKCC2.17R TATTAACATGGAGCACTAATTGTCT
NKCC2.18F 18 TTCATTTGTGATGGTAGTTTCCCAG 236 51
NKCC2.18R AAGTTATGTACTGCCCTGCTTAGTG
NKCC2.19F 19 GTAATACTAGTCCAAAGCTTGAG 212 55
NKCC2.19R TCAGGCACAAAGTAGGTGCTC
NKCC2.20F 20 TCTAGAAACTTTGTAGTTCTGAGTT 262 55
NKCC2.20R TTCATAGATGCTCAAATAGTGACTC
NKCC2.21F 21–22 TGTTTCTGCCCTCAAAAGCAAACAG 579 60
NKCC2.22R ATTAAAGCAACAAACCTCTGAAATG
NKCC2.23F 23 AAGCTAAGCTGAAATAAGACGTGAT 270 55
NKCC2.23R GATAATCAACACAAAAGAGAATGAG
NKCC2.24F 24 CTGTGAAATAATGAGTTAGTTTCCC 250 55
NKCC2.24R TGTTTCCTTTCTCAGCTAGTAAGAC
NKCC2.25F 25 GATGAGATTTTCTGCTTGTTCATGA 259 55
NKCC2.25R AATTCCCACCTGAAGAGTCCCAAGC
NKCC2.26F 26 CTAGTGCCGTTACTACCTATA G 285 54
NKCC2.26R TCAGATTTACAACATAAAGTACTGG
Abbreviations are: NKCC2, Na-K-2Cl cotransporter; PCR, polymerase chain reaction; T, annealing temperature.
traction Kit (Qiagen, Inc., Valencia, CA, USA). The
abundance and quality of DNA fragments were analyzed
by electrophoresis on 1.2% agarose gel, followed by ethid-
ium bromide staining and inspection under ultraviolet
light. Direct sequencing of double-strand DNA frag-
ments of exons of the 4 transporters was performed using
the internal sequencing primers shown in Tables 3 to 6
with an ABI PRISM BigdyeTM Thermal Cycle Sequenc-
ing Ready Reaction Kit (PE Applied Biosystems) and
an ABI model 310 autosequencer.
RESULTS
NKCC2 and ROMK genes
Sequence analysis of the NKCC2 and ROMK genes
from our 7 patients revealed 2 different mutations in the
NKCC2 gene and no mutation in the ROMK gene. One
mutation identified in patient A was a homozygous 3 bp
deletion at 732–734 in exon 5. This deletion results in
the deletion of Tyr at position 245. We investigated the
prevalence of the del245Tyr mutation in the Japanese
population by PCR. PCR-amplified DNA fragments
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Table 4. PCR primers for mutation analysis in ROMK
Size T
Primers Exon Sequence (5→3) bp C
ROMK 1F 1 CTGCCACGCCTACTCTTGTTGGATC 339 60
ROMK 1R GCGGGGAAAAGAGGTCTAAATTTTC
ROMK 2F 2 GATTACCTTCACCCAAATGTCTTTC 231 60
ROMK 2R AGCGTCTATGCACCAAATCTGTAAG
ROMK 3F 3 TCTGTGTGGGCCTGTCCTCTGTCTC 276 60
ROMK 3R TGTAGCCTGGGGTGTCCAATAGTTG
ROMK 4F 4 CACGACTCCACTATCAAATTAAGTG 267 55
ROMK 4R AGTTTCCATGACTGCATTAATGATG
ROMK 5Fa 5 CTTTCATGTGGGTCACCTAGTTCAC 469 55
ROMK 5Ra CCAATGGTCACTTGAGTCTCCAGAG
ROMK 5Fb TGCCAATCACACTCCCTGTGTGGAG 414 55
ROMK 5Rb CTACAAAGTTGATATTGATCTGGTC
ROMK 5Fc CACAGTCACTCCTGAAGGAGAGACC 532 55
ROMK 5Rc TCTAGGTACTAGGAGCTTTAGAGAC
Abbreviations are: PCR, polymerase chain reaction; ROMK, renal outer medullary K channel; T, annealing temperature. ROMK 5Ra, ROMK 5Fb, ROMK 5Rb,
and ROMK 5Fc were set within exon 5. Other primers were set within an intron.
Table 5. PCR primers for mutation analysis in ClC-Kb
Size T
Primers Exon Sequence (5→3) bp C
ClC-Kb 1F 1 ACTGGAAGGGCCTAGAGGCAGT 231 60
ClC-Kb 1R GATGTCCTGAGTGGTCCTCCAG
ClC-Kb 2F 2 TGCCCCACCCTGTGCCGTGAC 203 60
ClC-Kb 2R CTTGGCCCAGAGCAGCACCTG
ClC-Kb 3F 3 GAGGCTGTGGGTGCCTCCCTG 200 60
ClC-Kb 3R AGTGGGGACTGGCGTAGCGAC
ClC-Kb 4F 4 CCCTCCTGGCCCTGCCCAC 202 60
ClC-Kb 4R GGGTGGTTGGGATGCCCTCAC
ClC-Kb 5F 5–6 CGTGCTGACTCTGGGTGAGAC 356 72
ClC-Kb 6R GGAGGAGCTTGAGGGACCCAG
ClC-Kb 7F 7 GGAGGGCCCACCTGAGATCAG 193 72
ClC-Kb 7R GCAGGGCCAGGGTCAGGCAG
ClC-Kb 8F 8–9 CGCCATCTTGGCTCCCCACTG 374 65
ClC-Kb 9R AGCTCGCTGAGAGGTCCCCAG
ClC-Kb 10F 10 CAGCCCTAGAGCCCACCCATC 214 60
ClC-Kb 10R GGGCTTCCCCACTCCTGCCAC
ClC-Kb 11F 11 CCTCATGTCCAGTTCCCACCTG 246 60
ClC-Kb 11R GTCCCAGCTCTGTGCACACCTG
ClC-Kb 12F 12–13 TGTCCACGCCTTGCCCAGCAG 439 72
ClC-Kb 13R CACGACATTGCCCACGCAGCAG
ClC-Kb 14F 14 CTGCCTGACTCTGCCCTTGCAG 264 60
ClC-Kb 14R GACTCAGCCTGAGGTGGGCAC
ClC-Kb 15F 15 GACTGTGGGGCCTGATGGGAG 207 60
ClC-Kb 15R CCTACCCCCGACTTCCTCCTC
ClC-Kb 16F 16–17 GAACAGTTCTTGGCTAAGTAGGTG 454 60
ClC-Kb 17R CCAGAGGCCTCATGTGTCACAC
ClC-Kb 18F 18 GGGCACCTTCTACCCTCCAGTG 193 60
ClC-Kb 18R GTCTTCTCAGGCATAGGTTCCCTG
ClC-Kb 19F 19 CTACATCCCCCCGCACCTCCAC 215 72
ClC-Kb 19R GTTATGCCAAAGAATGGAGCTGG
Abbreviations are: PCR, polymerase chain reaction; ClC-Kb, Cl channel Kb; T, annealing temperature.
containing exon 5 from 100 unrelated subjects were elec-
trophoresed on 8% polyacrylamide gel, and a 3 bp dele-
tion could be detected based on differences in the elec-
trophoresis pattern. This screening did not identify
del245Tyr in any of the unrelated subjects. The second
mutation identified in patient A, B, C, D, F, and G was
a T-to-C substitution at position 1614 in exon 12, which
did not produce an amino acid substitution (homozy-
gotes, A, B, C, F, and G; heterozygote, D).
ClC-Kb gene
Five mutations in the ClC-Kb gene were identified in
5 of the 7 patients. One mutation found in patients B,
D, and E was a heterozygous T-to-G substitution at
position 80 in exon 1, which causes a Leu-to-Arg substitu-
tion at position 27. The second mutation found in patient
C was a heterozygous G-to-A substitution at position
1570 in exon 14, which causes a Val-to-Ile substitution
at position 524. Screening using direct sequencing de-
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Table 6. PCR primers for mutation analysis in NCCT
Size T
Primers Exon Sequence (5→3) bp C
NCCT 1F 1 CCTTGCGGATCCTGGCCCCTCCCTG 380 60
NCCT 1R GGTAGCTGGGTCGAGGTCACACAGC
NCCT 2F 2 GAGACGCCGTCCCTAGCACCCCTAC 240 60
NCCT 2R CATTTCTGGACATCACGCACCACCC
NCCT 3F 3 TTGGGGTGTCCACCCAGGTGGCCTC 189 60
NCCT 3R ATTCAGGCAAGCTGGGAAGAATGGG
NCCT 4F 4 ACTGGGGCTCCTCCCTTGGGAAATG 200 60
NCCT 4R ATTAGGAGCCCACGAGAGGAGGGCC
NCCT 5F 5 AGCCAACCGACTCATCTGGTTTCAT 244 60
NCCT 5R AGAGTGCAATGGGCTGCCCGGATCC
NCCT 6F 6 TGCCTCCTAGGTGGGCAGAGTCTGG 204 67
NCCT 6R TCTCCACGTGACCACCTCCATGTCC
NCCT 7F 7–8 GCTTCCCAGAGAGGTAGAACAAAAC 548 60
NCCT 8R GCTCATAGCCCCTGTGCAGTGCCAG
NCCT 9F 9 TCCCTCCTTCAGGACCCTGCTATAG 160 60
NCCT 9R TGGGACACTGCAGGGTGGAGGCCAG
NCCT 10F 10 GAAGAGGACAGAGTAAGGAGGGAAG 251 60
NCCT 10R CCCACTGTGTCTGGTGGGTCAGCTC
NCCT 11F 11 TCCTGGCTCAGCCCTCACCGTGGAG 205 60
NCCT 11R CCCAGGCTCCCCACCCCCTGTCATC
NCCT 12F 12 GGGAAGTGGCAGGTCCCAGCCTAAG 217 60
NCCT 12R GGAACAGGAGGCCAGGCCCTGTGAG
NCCT 13F 13 TCCTTGGCAGAGTTGCCCAACAGGC 223 60
NCCT 13R CACCCCATGCCCCAGTTCCTCCTGC
NCCT 14F 14 CCTAGAAAGAGGCTCGACTGCCAGG 277 60
NCCT 14R GGGCAGGGCCGCCTGCATGGCTACC
NCCT 15F 15 CGTGTCTGGTTTCCTCTAGTGATTC 229 60
NCCT 15R ACTCCCAGGGTGGAGCCATCACTGG
NCCT 16F 16 GGGCTCTCTCCTGATGGCTCCTGCC 218 65
NCCT 16R TGGGTTTACAGGCATGAGCCACCAT
NCCT 17F 17 TCTCAGGCTGGAGGGTGAAGGCAG 249 60
NCCT 17R GGTTGTGCCACCAAGCCGTAAGTCC
NCCT 18F 18 AGGTGGATCACCAACTCTGCCCCTC 252 60
NCCT 18R GCACCCACTACTTCTTTTCCACTTC
NCCT 19F 19 CCAGTGGGAGCTGGGGGAGAAGCTG 176 60
NCCT 19R AATGTGTTCTAGAACTTTCTGGGAG
NCCT 20F 20 CACGGTGCCCTCAGACAAGGAGAGC 176 60
NCCT 20R CCACAGGGCTAGAGTGCCCTGAGCT
NCCT 21F 21 CCTGGATGCGCGGCGCTGGCTCTGC 189 60
NCCT 21R GCCGGGCAGGAGGGCTGATCCAAGG
NCCT 22F 22 CTGTCCTGAGTGTATTCTTGTCATG 224 60
NCCT 22R TTGGGTGGAGCTAAGATGACACTGG
NCCT 23F 23 AGACAGAGCAAGACGCTGTCTCAAG 206 60
NCCT 23R GGGTCTCCAGGCACACAGTTGGCCC
NCCT 24F 24 TGGGGTTATCGTCTCAGCCGGCCTC 234 60
NCCT 24R CGTCCCTGACCCAGTGATGTGTCGC
NCCT 25F 25 CGTGGTGAAGGATTGAGTGACCTCG 186 60
NCCT 25R TGAGACACCTGACTCTGGACAGACT
NCCT 26F 26 TTTCATGCCTTGCAGCACTTTGCCC 253 60
NCCT 26R TCATCCCTGTGGACTAGAGGCAATC
Abbreviations are: PCR, polymerase chain reaction; NCCT, Na-Cl cotransporter; T, annealing temperature.
tected the heterozygous Val524Ile mutation in four of
the 100 unrelated subjects. The third mutation found in
patients B and E was a C-to-T substitution at position
1685 in exon 15, which causes a Thr-to-Met substitution
at position 562 (patient B, homozygote; patient E, het-
erozygote). The fourth mutation found in patients B and
E was a G-to-A substitution at position 1732 in exon 15,
which causes a Glu-to-Lys substitution at position 578
(patient B, homozygote; patient E, heterozygote). The
fifth mutation found in patients A, B, and E was a hetero-
zygous T-to-C substitution at position 1741 in exon 15,
which did not cause an amino acid substitution.
NCCT gene
Five mutations in the NCCT gene were identified in
6 of the 7 patients. One mutation found in patient B was
a heterozygous 18-base insertion next to position 811 in
exon 6 due to duplication. The sequence of this 18-base
insert was “ATTGGCGTGGTCTCGGTC.” This inser-
tion results in a 6-amino acid insertion (Ile-Gly-Val-Val-
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Table 7. Summary of variation identified in the seven patients
Transporter Allelesa Base position Location Amino acid position Amino acid change
NKCC2 del(CTA) 732–734 Exon 5 245 Deletion of Tyr
T/C 1614 Exon 12 538 No change
ClC-Kb T/G 80 Exon 1 27 Leu→Arg
G/A 1570 Exon 14 524 Val→Ile
C/T 1685 Exon 15 562 Thr→Met
G/A 1732 Exon 15 578 Glu→Lys
T/C 1741 Exon 15 581 No change
NCCT Insertion of 18 bpb Next to 804 Exon 6 Next to 268 Insertion of 6-amino acidb
C/T 2142 Exon 17 714 No change
T/A 2546 Exon 22 849 Leu→His
C/T 2598 Exon 22 866 No change
C/T 3025 Exon 26 1009 Arg→Stop
Abbreviations are: NKCC2, Na-K-2Cl cotransporter; ClC-Kb, Cl channel Kb; NCCT, Na-Cl cotransporter. Base position 1 is the first base of the initiator methionine.
a Reported nucleotide/detected nucleotide
b Nucleotide and amino acid sequences are described in the text
Table 8. Mutations detected in the seven patients
NKCC2 ClC-Kb NCCTTransporter
Exon 5 Exon 12 Exon 1 Exon 14 Exon 15 Exon 6 Exon 17 Exon 22 Exon 26
Mutation 732–734 1614 80 1570 1685 1732 1741 Next to 804 2142 2546 2598 3025
(CTA)del T/C T/G G/A C/T G/A T/C Ins18bp C/T T/A C/T C/T
Change del245Y NS L27R V524I T562M E578K NS Ins 6AA NS L849H NS R1009X
Patient A   – – – –  – – – – –
B –   –      –  
C –  –  – – – –    
D –   – – – – –  –  
E – –  –    –  –  
F –  – – – – – –  –  
G –  – – – – – –  –  
Abbreviations are: NKCC2, Na-K-2Cl cotransporter; ClC-Kb, Cl channel Kb; NCCT, Na-Cl cotransporter; , homozygous, , heterozygous, –, no detection.
cDNA position 1 is the first base of the initiator methionine. NS indicates no amino acid substitution.
Ser-Val) next to position 268. We investigated the preva-
lence of this 18-base insert in the Japanese population by
PCR. PCR-amplified DNA fragments containing exon 6
from 100 unrelated subjects were electrophoresed on
1.2% agarose gel. This 18-bp insertion could be detected
based on differences in electrophoresis patterns. Screen-
ing did not identify this 6-amino acid insertion in any of
the unrelated subjects. The second mutation found in
patients B, C, D, E, F, and G was a C-to-T substitution
at position 2142 in exon 17, which does not cause an
amino acid substitution (homozygotes, C, D, E, F, and
G; heterozygote, B). The third mutation found in patient
C was a heterozygous T-to-A substitution at position
2546 in exon 22, which causes a Leu-to-His substitution
at position 849. Screening using direct sequencing de-
tected the heterozygous Leu849His mutation in 3 of the
100 unrelated subjects. The fourth mutation found in
patients B, C, D, E, F, and G was a C-to-T substitution
at position 2598 in exon 22, which did not cause an
amino acid substitution (homozygotes, C, D, E, F, and
G; heterozygote, B). The fifth mutation found in patients
B, C, D, E, F, and G was a C-to-T substitution at position
3025 in exon 26, which introduces a preliminary stop
codon at position 1009 (homozygotes, D, E, F, and G;
heterozygotes, B and C). This mutation results in the
truncation of 13 amino acids from the carboxy-terminal
end of NCCT protein. We screened the Japanese popula-
tion for this Arg1009Stop mutation using direct sequenc-
ing, but did not find this mutation in any of the 100
unrelated subjects. All mutations identified in the pres-
ent study are shown in Tables 7 and 8.
Family study
Patient A. Patient A’s mother was found to carry het-
erozygous 3 bp deletion at 732–734 in NKCC2 exon 5.
Her parents did not have any apparent clinical symptoms.
Patient B. Patient B’s father was found to carry het-
erozygous NCCT R1009X mutation. Mother and 2 broth-
ers were found to carry heterozygous 18-base insertion
in NCCT exon 6. They did not have apparent clinical
symptoms or growth retardation and not show electro-
lyte disturbance in laboratory findings.
Patients C, D, E, F, and G. Only genomic DNA from
patients was available. Their parents or siblings did not
have any apparent clinical symptoms. Patients F and G
are offspring of a consanguineous couple.
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DISCUSSION
In the present study, we searched for abnormalities
or polymorphisms within 4 renal electrolyte transporter
genes in 7 patients with hypokalemic metabolic alkalosis.
As a result, 12 mutations were identified in 3 transporter
genes, excluding the ROMK gene. Four of these 12 muta-
tions did not affect the amino acid sequence of the re-
spective transporter protein.
In patient A, polyhydramnios occurred in pregnancy
and led to a preterm delivery. Her clinical symptoms
included growth retardation and hypercalciuria. She was
diagnosed as Bartter’s syndrome before this study. One
of her mutations in the NKCC2 gene was silent, but
another homozygous mutation in exon 5 (deletion of
CTA) resulted in a loss of Tyr at position 245. This
mutation has not been reported previously. In fact, an-
other type of NKCC, NKCC1, has also been identified
[14]. NKCC1, NKCC2, and NCCT are cation-Cl cotrans-
porters. All members of this family have 12 putative
transmembrane-spanning domains and show structural
and sequence similarity. Indeed, the amino acid se-
quence of NKCC2 is 61% identical to that of NKCC1,
and 50% identical to that of NCCT [15]. Tyr at position
245 is highly conserved in other species, as well as in the
corresponding position in human NKCC1 and NCCT.
In addition, Tyr at position 245 lies between the second
and third transmembrane domains, which are important
in cation transport [16]. Thus, it is reasonable to consider
that the deletion of Tyr could cause structural changes
in NKCC2 and contribute to the development of clinical
symptoms in patient A.
In the other 6 patients, the symptoms started in late
childhood and adolescence, and their clinical courses
were relatively mild. In ClC-Kb gene screening, we de-
tected 4 mutations that led to an amino acid exchange.
Three of these mutations (L27R, T562M, E578K) were
observed in the general population and were previously
considered to be innocuous polymorphisms [17]. In addi-
tion, we detected a V524I mutation, which has not been
reported previously. The heterozygous ClC-Kb V524I
mutation was observed in 4 of 100 unrelated Japanese
subjects. Since all mutations with amino acid exchange
in ClC-Kb were accompanied with mutations of NCCT
or NKCC2, further studies are needed to prove whether
this amino acid exchange affects ClC-Kb function and
clinical symptom in patients studied.
Analysis of the NCCT gene revealed that 6 patients
had a homozygous or compound heterozygous NCCT
gene mutation and shared a common novel mutation
that resulted in a substitution of Arg to a stop codon at
position 1009 in exon 26. Patients D and E, and F and G,
two pairs of siblings, were homozygous for this R1009X
mutation. Kunchaparty et al [18] reported that they in-
troduced a mutation into mouse NCCT, which truncated
the protein by 13 amino acids, and studied its functional
expression in Xenopus oocytes. Na uptake was almost
blocked in oocytes expressing this mutant NCCT clone.
NCCT shows structural and sequence similarity among
other species. For example, human NCCT is 93% identi-
cal to mouse NCCT in the 60 carboxy-terminal amino
acid residues. The mutation detected in human NCCT
in our study, R1009X, also truncates the protein by 13
amino acids at the corresponding position. Thus, it is
possible that the R1009X mutation impairs NCCT func-
tion. Patients B and C also carried mutations which re-
sulted in a 6-amino acid insertion in exon 6, and a Leu-to-
His substitution at position 849 in exon 22, respectively.
Thus, every 12th allele of the NCCT gene from these 6
patients was mutated. This means that all 8 parents of
these 6 patients were at least heterozygous for a NCCT
gene mutation. However, none had any apparent clinical
signs associated with hypokalemia. In addition, mutation
analysis of patient B’s family (parents and 2 siblings)
revealed that they had heterozygous NCCT mutations
without any clinical symptoms and electrolyte abnormal-
ities. Actually, sodium reabsorption by NCCT accounts
for only about 7% of all renal tubular sodium reabsorp-
tion. Therefore, NCCT dysfunction may lead to a rela-
tively mild loss of extracellular fluid or sodium loading
in collecting ducts, and a heterozygous mutation might
be insufficient to cause clinical symptoms. Thus, it is
reasonable to consider that the other 2 mutations, the
6-amino acid insertion and L849H, may impair NCCT
function. These 2 mutations had been reported pre-
viously in Japanese patients with Gitelman’s syndrome
by Tajima et al [19] as one allele in a compound heterozy-
gous mutation, and by Monkawa et al [20] as a heterozy-
gous mutation, respectively.
The 6 patients with a common mutant NCCT gene
were from a relatively small geographic area, the south-
ern area of Okinawa, with a population of about 80,000.
Although the worldwide prevalence of hypokalemic met-
abolic alkalosis has not yet been established, one study
published in 1988 estimated it to be 19 cases per million
in Goteborg, Sweden [21]. Compared with this previous
study, the frequency among our subjects appears to be
high. In isolated populations, the incidence of relatively
rare recessive disorders tends to be higher than that in
the general population. Thus, this mutation may have
been introduced into the population by a single founder.
With respect to genotype-phenotype correlation, it has
been widely accepted that patients with mutant NCCT
genes have Gitelman’s syndrome [8]. Our patients with
mutant NCCT gene can be diagnosed as Gitelman’s syn-
drome, except for patients C and E. They did not show
hypomagnesemia. Hypomagnesemia in patients with Gi-
telman’s syndrome is caused by renal magnesium wasting
[22]. Thus, we evaluated fractional excretion of magne-
sium (FEMg) in patients C and E. Their FEMg were not
increased (FEMg in patients C and E were 0.8 and 2.2%,
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respectively. Normal FEMg is less than 4%). The reason
for hypomagnesemia in Gitelman’s syndrome is still un-
known, but it is considered to be the direct consequence
of impaired NCCT function for several reasons. First,
hypomagnesemia is also observed following the adminis-
tration of thiazide diuretics, which inhibit NCCT [23].
Second, an analogous dissociation of renal handling of
calcium and magnesium has been observed in NCCT-
knockout mice [24]. However, the phenotype-genotype
discrepancy in Gitelman’s and Bartter’s syndromes is not
a novel observation. Recently, Peters et al [9] reported
phenotype observations along with a molecular diagno-
sis. In their study, 3 of 13 patients with NCCT defect did
not have typical hypomagnesemia. Zelikovic I et al [25]
reported a novel mutation in the ClC-Kb gene as a cause
of Gitelman’s and Bartter’s syndromes. Their 12 patients
with hypokalemic tubulopathy were homozygous for a
R438H mutation in ClC-Kb gene. Four of 12 patients
had hypomagnesemia and hypocalciuria. With respect to
renal magnesium handling, Ca2-sensing receptor (CASR)
and ion channels belonging to the transient receptor
potential (TRP) channel family are reported as regula-
tors of renal magnesium reabsorption [26–30]. Although
further studies are needed for clarifying the renal magne-
sium handling in patients with mutant NCCT genes, it
seems rational to consider that in some patients without
hypomagnesemia, such as our patients C and E, these or
unknown magnesium regulators may compensate renal
magnesium wasting caused by NCCT defect.
CONCLUSION
Many studies have reported how to differentiate be-
tween Gitelman’s syndrome and classic Bartter’s syn-
drome based on laboratory findings or clinical examina-
tion. Recent advances in molecular genetics may make
it both faster and easier to diagnose and differentiate these
diseases. Antenatal Bartter’s syndrome requires early res-
cue and special attention, and classic Bartter’s syndrome
is also not always mild—severe complications may occur.
In contrast, Gitelman’s syndrome has been considered
a benign disease. However, complicated cases in patients
with Gitelman’s syndrome have recently been reported,
including a case of end-stage renal failure [31, 32]. Regu-
lar check-ups and appropriate treatment should be re-
quired in either case. Considering the genotype-pheno-
type overlap seen in these cases, we may wish to revise
terms “Bartter’s syndrome” and “Gitelman’s syndrome”
based only on serum magnesium and urine calcium.
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